Filtered By:
Education: Study
Procedure: Heart Transplant
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 644 results found since Jan 2013.
Early postoperative effects of kidney transplantation on the cardiovascular system in our clinical practice
CONCLUSION: After transplantation, the left atrial and the end-systolic diameter of the left ventricle regrediated, decreasing the frequency of arrhythmic episodes. The number of the middle grade mitral valve regurgitation decreased and the calcification among diabetic population increased significantly. Orv Hetil. 2021; 162(26): 1052-1062.PMID:34175832 | DOI:10.1556/650.2021.32269
Source: Orvosi Hetilap - June 27, 2021 Category: General Medicine Authors: Andrea Darag ó Gerda Schwegler Eszter Szab ó Dorina Bark ó R éka P Szabó Attila Csaba Nagy Gerg ő József Szőllősi Bal ázs Nemes Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Primary results of long ‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants
ConclusionsThe primary results of accumulating HM3 LVAD experience suggest a lower adverse event burden and similar survival compared to the pivotal MOMENTUM 3 trial.
Source: European Journal of Heart Failure - May 19, 2021 Category: Cardiology Authors: Mandeep R. Mehra,
Joseph C. Cleveland,
Nir Uriel,
Jennifer A. Cowger,
Shelley Hall,
Douglas Horstmanshof,
Yoshifumi Naka,
Christopher T. Salerno,
Joyce Chuang,
Christopher Williams,
Daniel J. Goldstein, on behalf of the MOMENTUM 3 Investigator Tags: Research Article Source Type: research
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Primary Results of Long ‐Term Outcomes in the MOMENTUM 3 Pivotal Trial and Continued Access Protocol Study Phase: A Study of 2200 HeartMate 3 Left Ventricular Assist Device Implants
ConclusionsThe primary results of accumulating HM3 LVAD experience suggest a lower adverse event burden and similar survival compared to the pivotal MOMENTUM 3 trial.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - May 1, 2021 Category: Cardiology Authors: Mandeep R. Mehra,
Joseph C. Cleveland,
Nir Uriel,
Jennifer A. Cowger,
Shelley Hall,
Douglas Horstmanshof,
Yoshifumi Naka,
Christopher T. Salerno,
Joyce Chuang,
Christopher Williams,
Daniel J. Goldstein,
on behalf of the MOMENTUM 3 Investigators Tags: Research Article Source Type: research
Space Can Take a Nasty Toll On An Astronaut ’s Heart, Study Finds
It’s perfectly fine that human beings want to travel in space. But we have to reckon with the fact that space doesn’t want anything to do with us. The exterior environment of space, of course, represents instantaneous death, what with the killing cold and the absence of any atmosphere. But even inside a spacecraft or a space station—cozy, pressurized, temperature-controlled, with food supplies, comfortable sleep pods, and a zero-g privy to take care of unavoidable essentials—the body doesn’t care for space.
Space radiation, which makes it through the walls of even the sturdiest ship, raises an...
Source: TIME: Science - April 2, 2021 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Source Type: news
Neurologic Complications After Pediatric Heart Transplant: A Single-Center Experience
CONCLUSIONS: Neurologic complications may lead to serious mortality and morbidity in pediatric heart transplant patients. Seizures, posterior reversible encephalopathy syndrome, stroke, peripheral neuropathy, transient ischemic attack, and cerebral infections are the most common neurologic complications, which are seen in the perioperative period in particular. Careful follow-up of pediatric heart transplant patients, with detection and early treatment of neurologic findings, will contribute to lower rates of sequelae. To our knowledge, this is the largest study to show a detailed experience of neurologic complications in ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - April 2, 2021 Category: Transplant Surgery Authors: Ali Orgun Ilkay Erdogan Birg ül Varan Taner Sezer N K ürsad Tokel Murat Özkan Atilla Sezgin Source Type: research
Mechanical Circulatory Support Prior to Heart Transplantation Predicts Early Post-Operative Stroke
CONCLUSIONS: With the exception of left ventricular assist devices, use of MCS modalities leading to HT is significantly and independently associated with stroke during the early post-HT period.PMID:33785302 | DOI:10.1016/j.amjms.2021.03.008
Source: The American Journal of the Medical Sciences - March 31, 2021 Category: General Medicine Authors: Trenton J Bickel Prasad Gunasekaran Deepak K Parashara Martin A Alpert Source Type: research
